This ISS National Lab Research Announcement (NLRA) is issued in collaboration with NASA’s Biological and Physical Sciences (BPS) division and seeks proposals for flight projects that utilize the unique space environment to address challenges that hinder progress in preventing, diagnosing, and treating some of the most challenging diseases of our time, such as cancer. Similarly, advanced therapies for cardiovascular, immune, muscle and bone, and neurodegenerative diseases face obstacles that thwart scientific advancements and the translation of research findings into clinical applications. These challenges frequently overlap and share common elements, despite the complexity and variability of mechanisms within and among these diseases. Many of these challenges can be mitigated using accelerated disease models in microgravity. This NLRA aims also to foster collaborations between academia, industry, and government to tackle complex challenges and develop innovative, commercially viable products and technologies for disease prevention, diagnosis, and treatment to improve medical outcomes on Earth.
CASIS intends to select for award spaceflight projects leading to defined milestones in technological innovation on a roadmap that aligns with national R&D priorities and the ISS National Lab mission to benefit humanity and the U.S. economy. In evaluating proposals, CASIS prioritizes the scientific and technical merit of the proposal as well as its feasibility and potential benefit to value creation for the nation and the emerging low Earth orbit ecosystem. The ISS National Lab strives for a balanced project award portfolio that accounts for diverse factors, including, but not limited to, different types of institutional representation, participation by individuals traditionally underrepresented in STEM areas and careers, and the assembly of teams promote inclusion, diversity, equity, and accessibility (IDEA) for improving workforce development.
This research announcement will follow a three-step proposal submission process.
All interested investigators must first complete and submit for review a Step 1A: Concept Summary. Offerors with approved concepts will be invited to submit a Step 1B: Technology Roadmap. Offerors with approved Technology Roadmaps will then be invited to submit a Step 2: Full Proposal.
APPLICANT RESOURCES
View Applicant Resources for ISS National Lab Research Opportunities
WEBINAR
Step 1A: Download NLRA 2024-9 Instructions and Required Step 1A Forms
Download Step 1A: Concept Summary Required Forms
• Step 1A: Concept Summary Due Date: September 26, 2024
Step 1A: Concept Summary Online Submission
Concept summaries must be submitted electronically using the concept summary submission form. To access the form, press the “Click to Submit” button below. Please follow the directions on that page.Step 1B: Download NLRA 2024-9 Step 1B Required Forms (Invitation Only)
CASIS will notify all offerors of the review results of their Step 1A: Concept Summary.
Download Step 1B Required Forms
• Step 1A: Concept Summary Due Date: November 22, 2024
Step 1B: Technology Roadmap Online Submission
Technology roadmaps must be submitted electronically using the technology roadmap submission form. To access the form, press the “Click to Submit” button below.
Step 2.1: Download Step 2 Required Forms (Invitation Only)
CASIS will notify all offerors of the review results of their Step 1B: Technology Roadmap.
Download Step 2 Required Forms
- : Step 2: Full Proposal Due Date: March 3, 2024
Step 2.2: Full Proposal Submission
Offerors invited to submit a Step 2: Full Proposal can access the online proposal submission form by pressing the “Click to Submit” button below. Please follow the directions on that page.
Thank you for your interest in conducting research through the ISS National Lab. For questions regarding this research announcement, please contact [email protected] and reference NLRA 2024-9 in the subject line.
** Please verify that none of the information submitted is subject to the export control laws of the United States, such as the EAR or the ITAR; if any information is subject to such laws, please mark all pages containing such information and identify the appropriate export control jurisdiction and classification. **
